Editorial
doi: 10.1212/WNL.0000000000209970.
Epub 2024 Oct 1.
Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines
Affiliations
- PMID: 39353150
- DOI: 10.1212/WNL.0000000000209970
Item in Clipboard
Editorial
Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines
Neurology.
.
Erratum in
-
Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines.Neurology. 2024 Dec 24;103(12):e210162. doi: 10.1212/WNL.0000000000210162. Epub 2024 Nov 19. Neurology. 2024. PMID: 39561311 No abstract available.
No abstract available
Similar articles
-
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.Lancet Neurol. 2013 Jun;12(6):554-62. doi: 10.1016/S1474-4422(13)70076-0. Epub 2013 Apr 26. Lancet Neurol. 2013. PMID: 23623397
-
Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: A case report.Mult Scler. 2025 Apr;31(5):615-617. doi: 10.1177/13524585241283648. Epub 2025 Jan 22. Mult Scler. 2025. PMID: 39844614
-
Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.J Neurol. 2024 May;271(5):2866-2870. doi: 10.1007/s00415-023-12071-9. Epub 2023 Nov 14. J Neurol. 2024. PMID: 37962590 Free PMC article.
-
Recent advances in the treatment of neuromyelitis optica spectrum disorders.Curr Opin Rheumatol. 2021 May 1;33(3):233-239. doi: 10.1097/BOR.0000000000000791. Curr Opin Rheumatol. 2021. PMID: 33741809 Review.
-
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases.Curr Opin Neurol. 2020 Jun;33(3):362-371. doi: 10.1097/WCO.0000000000000813. Curr Opin Neurol. 2020. PMID: 32304439 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
